AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. [electronic resource]
Producer: 20150623Description: 533-46 p. digitalISSN:- 1878-3686
- Animals
- Antibodies, Monoclonal, Humanized -- pharmacology
- Carcinoma, Squamous Cell -- metabolism
- Cell Line, Tumor
- Cetuximab
- Class I Phosphatidylinositol 3-Kinases
- Drug Resistance, Neoplasm
- Esophageal Neoplasms -- metabolism
- Esophageal Squamous Cell Carcinoma
- Head and Neck Neoplasms -- metabolism
- Humans
- Mice
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase C -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- genetics
- Receptor Protein-Tyrosine Kinases -- genetics
- Signal Transduction
- TOR Serine-Threonine Kinases -- metabolism
- Thiazoles -- pharmacology
- Xenograft Model Antitumor Assays
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.